The therapeutic efficacy of ICIs relies on augmentation of the anti-tumor immune response, mediated by presentation of tumor-specific neoantigens primarily by major histocompatibility complex (MHC) class I proteins, along with multiple co-stimulatory signals, and resultant CD8+ effector cell activation. This evidence concerns the gene CD8A and neoplasm.